The Wegovy Summary of Product Characteristics (SmPC) specifically states that concomitant use with other weight-loss medicinal products is not recommended, as safety and efficacy have not been established
Seek immediate medical attention (call 911 for severe symptoms) if you experience: Chest pain, pressure, or discomfort, particularly if new or worsening Severe shortness of breath or difficulty breathing at rest Rapid or irregular heartbeat accompanied by dizziness or lightheadedness Swelling in the legs, ankles, or abdomen that develops suddenly or worsens Unexplained fatigue or exercise intolerance that significantly limits daily activities These symptoms may indicate cardiovascular complications unrelated to tirzepatide itself but requiring urgent evaluation, especially in patients with diabetes and obesity who have elevated baseline cardiovascular risk
#PeptideAPI #OligonucleotideAPI #PeptideDrugs #Oligonucleotides #QC #AnalyticalChemistry #PharmaceuticalAnalysis #AnalyticalDevelopment #MethodDevelopment #MethodValidation #AnalyticalChallenges #LCMS #MassSpectrometry #HPLC #UHPLC #CapillaryElectrophoresis #NMR #ImpurityProfiling #StabilityStudies #QualityControl #QualityAssurance #GMP #cGMP #ICHGuidelines #ICHQ2 #ICHQ14 #RegulatoryAffairs #DrugDevelopment #Biopharmaceuticals #PharmaceuticalInnovation #SIPHACOS #Testing #Analysis #AnalyticalChallenges #566 SIPHACOS Analytical Challenges in Peptide and Oligonucleotide APIs To view or add a comment, sign in New from Agilent: 13Peptide LC/MS Standard Reliable data starts with confident system performance
Tirzepatide achieves reductions of up to 2.0 to 2.3 percentage points, which is among the largest A1c improvements seen with any diabetes medication
Some clients feel a warm flush, slight chest pressure, or mild stomach discomfort during NAD+ infusions
